FDA To Review Pfizer’s RSV Vaccine Candidate For Older Adults On Priority

Reuters (12/7, Satija, Mandowara) reports Pfizer “said on Wednesday the U.S. Food and Drug Administration will review its respiratory syncytial virus (RSV) vaccine candidate on priority.” Pfizer “is seeking approval for use of the vaccine, RSVpreF, in adu...